Correlates of osteoprotegerin levels in women and men

Osteoporosis International

Volumn 13, Issue 5, 2002, Pages 394-399

  Khosla, S ^a   Arrighi, H M ^b   Melton III, L J ^a   Atkinson, E J ^a   O'Fallon, W M ^a   Dunstan, C ^b   Riggs, B L ^a  

^a MAYO CLINIC   (United States)

^b AMGEN INC   (United States)

Author keywords

BMD; Bone turnover; OPG; RANK L; Sex steroids

Indexed keywords

ESTROGEN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TESTOSTERONE;

ADULT; AGED; AGING; ARTICLE; BONE ATROPHY; BONE DENSITY; BONE MINERAL; BONE TURNOVER; ESTROGEN BLOOD LEVEL; FEMALE; HOMEOSTASIS; HUMAN; MAJOR CLINICAL STUDY; MALE; OSSIFICATION; OSTEOLYSIS; POSTMENOPAUSE; PRIORITY JOURNAL; SEX DIFFERENCE; TESTOSTERONE BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; AGING; BONE REMODELING; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESTRADIOL; FEMALE; GLYCOPROTEINS; HUMANS; MALE; MIDDLE AGED; OSTEOPROTEGERIN; POSTMENOPAUSE; PREMENOPAUSE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; SEX CHARACTERISTICS; STATISTICS, NONPARAMETRIC; TESTOSTERONE;

EID: 0036283034     PISSN: 0937941X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001980200045     Document Type: Article

References (24)

1. Osteoprotegerin (OPG) ligand is a cytokine that regulates osteoclast differentiation and activation
2. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL
3. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density
4. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification
5. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin
6. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption
7. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells
8. 17β-Estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-β
9. Regulation of osteoprotegerin gene expression and protein production by androgens and anti-androgens in human osteoblastic cells
10. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: Increased serum concentrations in postmenopausal women with osteoporosis
11. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women
12. Characterization of monomeric and homodimeric forms of osteoclastogenesis inhibitory factor
13. Characterization of structural domains of human osteoclastogenesis inhibitory factor
14. History of the Rochester Epidemiology Project
15. The influence of osteophytes and aortic calcification on spinal mineral density in postmenopausal women
16. The measurement of sex steroid binding globulin by differential ammonium sulphate precipitation
17. Plasma concentrations of free and non-TeBG bound testosterone in women on oral contraceptives
18. Increase in serum bone γ-carboxyglutamic acid protein with aging in women: Implications for the mechanism of age-related bone loss
19. Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly men
20. Characterization of aromatase and 17β-hydroxysteroid dehydrogenase expression in rat osteoblastic cells
21. Osteoprotegerin serum levels in men: Correlation with age, estrogen, and testosterone status
22. Evidence that postmenopausal women with vertebral fractures due to type I osteoporosis have enhanced responsiveness of bone to estrogen deficiency
23. Characterization of monomeric and homo-dimeric forms of osteoclastogenesis inhibitory factor
24. ELISA methodology for detection of modified osteoprotegerin in clinical studies